GlassScriptPhysician profile
Mallory Jones
NPI 1285136382
$9,720.34
in general payments reported to CMS, 2019-2025
28 companies · $2,278 in 2025
The $2,278 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,792 · 2022: $1,462 · 2023: $2,219 · 2024: $1,970 · 2025: $2,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,198 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,197.68 |
| Education | $268.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,686.10 | 2021-2025 | |
| Lilly USA, LLC | $1,087.01 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $834.47 | 2021-2025 | Tremfya |
| Genzyme Corporation | $682.77 | 2021-2025 | |
| Amgen INC. | $648.54 | 2021-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $633.31 | 2021-2025 | Ilumya, Winlevi, Odomzo |
| Regeneron Healthcare Solutions, INC. | $590.84 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $381.36 | 2021-2025 | |
| Allergan, INC. | $373.32 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $314.31 | 2022-2024 | Sotyktu |
| Organogenesis INC. | $242.01 | 2021-2024 | |
| Pfizer INC. | $241.65 | 2021-2025 | |
| Galderma Laboratories, L.P. | $196.40 | 2021-2025 | Nemluvio |
| Incyte Corporation | $188.81 | 2022-2025 | Opzelura |
| Dermavant Sciences, INC. | $142.56 | 2024 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.65 | 2022-2025 | Spevigo |
| Almirall LLC | $72.06 | 2024-2025 | Klisyri |
| Organon LLC | $53.24 | 2025 | Vtama, Nexplanon |
| Ucb, INC. | $46.71 | 2021 | |
| Arcutis Biotherapeutics, INC. | $37.76 | 2024-2025 | Zoryve |
| Biofrontera INC. | $28.33 | 2022-2024 | Xepi, Bf-Rhodoled, Rhodoled Xl |
| Botanix Sb INC | $27.42 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $26.75 | 2023 | Ycanth |
| Convatec INC. | $23.88 | 2023 | |
| Mayne Pharma Commercial LLC | $23.14 | 2023 | |
| Lnhc, INC | $20.71 | 2025 | Zelsuvmi |
| Leo Pharma INC. | $14.70 | 2022 | |
| Genentech USA, INC. | $12.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.